@article{38e0593ba84342f3b58695d7478b043a,
title = "Moving the Needle Forward with Locoregional Treatment in Unresectable Cholangiocarcinoma - The Jury Is Still Out",
author = "Scott, \{Aaron J.\} and Shroff, \{Rachna T.\}",
note = "Funding Information: Conflict of Interest Disclosures: Dr Scott reported receiving personal fees from Exelixis, FivePrime, Genentech, and Incyte outside the submitted work; is a paid advisory board member for Exelixis Pharmaceuticals; and has received research funding from FivePrime Therapeutics, Exelixis Pharmaceuticals, Genentech, and Incyte Corporation. Dr Shroff reported receiving grants and personal fees from Merck, Exelixis, and QED Therapeutics; personal fees from Agios, Seattle Genetics, and Debio Pharm; grants from Pieris, Taiho, and Halozyme outside the submitted work; is a paid advisory board member for Merck, Seattle Genetics, Exelixis Pharmaceuticals, QED Therapeutics, and Debiopharm; and is a paid consultant for Agios. 31 10 2019 09 01 2020 January 2020 6 1 29 31 16 08 2019 19 08 2019 Copyright 2019 American Medical Association. All Rights Reserved. ced190018.pdf ",
year = "2020",
month = jan,
doi = "10.1001/jamaoncol.2019.3691",
language = "English (US)",
volume = "6",
pages = "29--31",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "1",
}